Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.58 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.58 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.58 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.58 |
| ▸ | MELK | Q14680 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.31 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.31 |
| ▸ | CLK1 | P49759 | 3/20 | 0.31 |
| ▸ | CLK2 | P49760 | 3/20 | 0.31 |
| ▸ | CLK3 | P49761 | 3/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.31 |
| ▸ | DYRK4 | Q9NR20 | 3/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873790 | 1.00 | TLK2 (0.58) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL7661988 | 1.00 | TLK2 (0.58) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL5873809 | 0.79 | MAP3K11 (0.59) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL5873811 | 0.79 | MAP3K11 (0.59) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL2356090 | 0.74 | MAP3K11 (0.55) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL2230665 | 0.74 | TLK2 (1.00) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL1395126 | 0.74 | TLK2 (1.00) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL1395124 | 0.74 | TLK2 (1.00) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL16231608 | 0.73 | MAP3K11 (0.61) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL16234132 | 0.73 | MAP3K11 (0.68) | TLK2MAP3K11NEK7NEK6MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| EP-1009738-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6541503-B2 | Preventing chemotherapy induced alopecia. | SMITHKLINE BEECHAM CORPORATION | 2003-04-01 | — | — | US | disclosed |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-01-02 | — | — | US | disclosed |
| US-6498176-B1 | INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS | SMITHKLINEBEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6387919-B1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | GLAXO WELLCOME INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| EP-1009738-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | TLK2 368/4885MAP3K11 75/4885NEK7 427/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | TLK2 311/4885MAP3K11 97/4885NEK7 423/4885 |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | TLK2 241/4885MAP3K11 270/4885NEK7 715/4885 |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | CDK2, CDK1, CCNI | TLK2 256/4885MAP3K11 203/4885NEK7 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.